share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

SEC announcement ·  Mar 21 16:08
Summary by Moomoo AI
Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.
Redhill Biopharma Ltd., a foreign private issuer, has successfully passed a resolution to increase its authorized share capital at the Extraordinary General Meeting of Shareholders held on March 21, 2024. The resolution was approved by the company's shareholders, as reported in the Form 6-K filed with the United States Securities and Exchange Commission. This corporate action is now incorporated by reference into the company's various Registration Statements on Forms S-8 and F-3, which have been previously filed with the SEC on specified dates ranging from May 2, 2013, to October 13, 2023. The Form 6-K serves as a legal document that ensures the company adheres to the SEC regulations by providing timely updates on significant corporate events.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more